How is DNSP-11 administered?
This describes how DNSP-11 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous (intra-cranial in animal models), on a daily in animal protocols schedule, generally over pre-clinical. Specific dosing is individual and beyond general information, and human evidence for DNSP-11 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous (intra-cranial in animal models)
- Schedule: Daily in animal protocols
- Cycle length: Pre-clinical
- Half-life: Short (minutes)
References
- Dopamine neuron stimulating actions of a GDNF propeptide — Bradley LH, Fuqua J, Richardson A, et al. (Gerhardt GA group). PLoS One, 2010
- Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques — Stenslik MJ, Evans A, Pomerleau F, et al. (Gerhardt GA, Bradley LH groups). Journal of Neuroscience Methods, 2018
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on DNSP-11
Last updated 2026-06-15.